NCT03297606
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+, HER2, HER3, HER4, VEGFR, EGFR, FGFR, CDK, Akt, mTOR, PI3K, ALK, ROS, MET, KIT, PDGFR, POLE, POLD, RET, FLT, CSFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Any patient with an incurable metastatic solid tumor is eligible; The trial matches patients to a specific experimental arm based on mutations expressed by the tumor- see trial for full list of eligible mutations
Exclusions: Known active progressive brain metastases
https://ClinicalTrials.gov/show/NCT03297606